Pasar al contenido principal

IDENTIFICACION Y CARACTERIZACION DE RNAS NO CODIFICANTES PARA EL TRATAMIENTO DE ENFERMEDADES HEPATICAS

SAF2012-40003

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Nacional de Proyectos de Investigación Fundamental
Subprograma Subprograma de Proyectos de Investigación Fundamental no Orientada
Convocatoria Proyectos I+D
Año convocatoria 2012
Plan Estatal 2008-2011 Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica
Unidad de gestión Secretaría de Estado de Investigación, Desarrollo e Innovación
Centro beneficiario FUNDACION PARA LA INVESTIGACION MEDICA APLICADA
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Insulin-like Growth Factor I (IGF-I) expressed from an AAV1 vector leads to a complete reversion of liver cirrhosis in rats

  • Sobrevals, Luciano
  • Enguita Germán, Mónica
  • Quiroga, Jorge
  • Prieto, Jesús
  • Fortes, Puri
IGF-I modulates liver tissue homeostasis. It is produced by hepatocytes and signals within the liver through IGF-I receptor expressed on hepatic stellate cells (HSCs). Liver cirrhosis is characterized by marked IGF-I deficiency. Here we compared the effect of two different gene therapy vectors encoding IGF-I as a potential treatment for cirrhotic patients. Rats with carbon tetrachloride-induced liver cirrhosis were treated with controls or with adeno-associated virus 1 (AAV) or simian virus 40 (SV40) vectors expressing IGF-I (AAVIGF-I or SVIGF-I) and molecular and histological studies were performed at 4 days, 8 weeks and 16 weeks. Increased levels of IGF-I were observed in the liver as soon as 4 days after vector administration. Control cirrhotic rats showed increased hepatic expression of pro-inflammatory and pro-fibrogenic factors including transforming growth factor beta (TGFβ), tumor necrosis factor-alpha (TNFα), connective tissue growth factor (CTGF), and vascular endothelial growth factor (VEGF) together with upregulation of α-smooth muscle actin (αSMA), a marker of HSC activation. In IGF-I-treated rats the levels of all these molecules were similar to those of healthy controls by week 8 post-therapy. Of note, the decline of TGFβ, CTGF, VEGF and αSMA expression was more rapid in AAVIGF-I treated animals reaching statistical significance by day 4 post-therapy. IGF-I-treated rats showed similar improvement of liver function tests in parallel with upregulation of hepatocyte nuclear factor 4α (HNF4α), a factor that promotes hepatocellular differentiation. A significant decrease of liver fibrosis, accompanied by upregulation of the hepatoprotective and anti-fibrogenic hepatocyte growth factor (HGF), occurred in all IGF-I-treated rats but complete reversal of liver cirrhosis took place only in AAVIGF-I group. Therefore, AAVIGF-I reverts liver cirrhosis in rats, a capability which deserves clinical testing., This study was supported by grants from the Ministry of Science and Innovation (SAF2012-40003 and SAF2015-70971-R), CIBERehd and Fondo de Investigación Sanitaria (PI14/01442), financed by the Instituto de Salud Carlos III, Fundació La Marató de TV3 (20132132), Caja Navarra Foundation (70020), European FEDER funding and by the project RNAREG [CSD2009-00080], funded by the Ministry of Science and Innovation under the program CONSOLIDER INGENIO 2010.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Long noncoding RNA EGOT negatively affects the antiviral response and favors HCV replication

  • Carnero, Elena
  • Barriocanal, Marina
  • Prior, Celia
  • Unfried, Juan Pablo
  • Segura, Víctor
  • Guruceaga, Elizabeth
  • Enguita Germán, Mónica
  • Smerdou, Cristian
  • Gastaminza, Pablo
  • Fortes, Puri
Acceso cerrado a este documento. No se encuentra disponible para la consulta pública. Depositado en Academica-e para cumplir con los requisitos de evaluación y acreditación académica del autor/a (sexenios, acreditaciones, etc.)., The role of long noncoding RNAs (lncRNAs) in viral infection is poorly studied. We have identified hepatitis C virus (HCV)‐Stimulated lncRNAs (CSRs) by transcriptome analysis. Interestingly, two of these CSRs (PVT1 and UCA1) play relevant roles in tumorigenesis, providing a novel link between HCV infection and development of liver tumors. Expression of some CSRs seems induced directly by HCV, while others are upregulated by the antiviral response against the virus. In fact, activation of pathogen sensors induces the expression of CSR32/EGOT. RIG‐I and the RNA‐activated kinase PKR sense HCV RNA, activate NF‐κB and upregulate EGOT. EGOT is increased in the liver of patients infected with HCV and after infection with influenza or Semliki Forest virus (SFV). Genome‐wide guilt‐by‐association studies predict that EGOT may function as a negative regulator of the antiviral pathway. Accordingly, EGOT depletion increases the expression of several interferon‐stimulated genes and leads to decreased replication of HCV and SFV. Our results suggest that EGOT is a lncRNA induced after infection that increases viral replication by antagonizing the antiviral response., This work was supported by grants from the Ministry of Economy (SAF2012-40003, BFU2013-50517-EXP, SAF2015-70971-R), grant Ortiz de Landazuri from the Government of Navarra, Fundacio La Marato de TV3 (20132130-31-32), Caja Navarra Foundation (70020), European FEDER funding and by the project RNAREG [CSD2009-00080], funded by the Ministry of Science and Innovation under the program CONSOLIDER INGENIO 2010. MB is the recipient of a FPI fellowship.